Negative symptoms in schizophrenia Treatment

Understanding Treatment Goals for Negative Symptoms

When someone lives with schizophrenia, they may experience what doctors call negative symptoms—challenges that involve a loss or reduction of normal abilities and behaviors. These symptoms can include difficulty feeling motivated, reduced emotional expression, withdrawal from social contact, decreased speech, and diminished ability to experience pleasure. Treatment for these symptoms focuses on helping people regain their ability to function in daily life, maintain relationships, and participate in work or education.1

The approach to treating negative symptoms depends heavily on each person's unique situation, including the stage of illness, other symptoms they may be experiencing, and their overall health. While positive symptoms of schizophrenia—such as hallucinations and delusions—often respond well to standard medications, negative symptoms present a more complex challenge for healthcare providers. Medical societies have established treatment guidelines, and researchers continue to explore new therapies through clinical trials to find better solutions for these persistent difficulties.1

Understanding the difference between primary negative symptoms—those that arise directly from schizophrenia itself—and secondary negative symptoms—those caused by other factors like medication side effects, depression, or social isolation—is essential for effective treatment. Secondary negative symptoms may improve when the underlying cause is addressed, while primary symptoms typically require more specialized approaches.2

Standard Treatment Approaches

The foundation of treating negative symptoms begins with antipsychotic medications. First-generation antipsychotics, also called typical antipsychotics, were revolutionary when introduced in the 1950s because they dramatically reduced hallucinations and delusions in about 70 to 80 percent of patients. However, these older medications have limited effect on negative symptoms and can sometimes worsen them through side effects like muscle stiffness, sedation, and what doctors call extrapyramidal symptoms—movement problems that can look similar to negative symptoms themselves.3

Second-generation antipsychotics, sometimes called atypical antipsychotics, have shown more promise for negative symptoms. Among these, cariprazine has demonstrated particular benefit. This medication works differently from older antipsychotics by affecting both dopamine and serotonin receptors in the brain in a unique way. In clinical studies comparing cariprazine to risperidone in patients who had recovered from acute psychosis but continued experiencing negative symptoms, cariprazine showed superior results, though the improvement was modest—about nine patients would need to be treated for one to show significant benefit.45

Amisulpride, an antipsychotic available in Europe (and potentially coming to the United States market), has also shown favorable results in large trials specifically targeting negative symptoms. Other second-generation antipsychotics including olanzapine, clozapine, and asenapine have demonstrated some effectiveness, though the evidence is strongest when these medications are used during active psychosis rather than for isolated negative symptoms.4

Clozapine deserves special mention because, although it's not specifically approved for negative symptoms, it has shown the largest effect in reducing them compared to other antipsychotics—with an effect size of 0.6 in research studies. This medication also leads to higher rates of functional recovery, meaning patients are better able to return to work, maintain relationships, and live independently. However, clozapine requires regular blood monitoring due to potential serious side effects, which limits its use to patients who haven't responded to other treatments.5

Antidepressant medications are sometimes added to antipsychotic treatment, particularly when depression coexists with negative symptoms. Selective serotonin reuptake inhibitors (SSRIs) have shown generally positive results, though the benefits tend to be small. Other antidepressants including duloxetine, mirtazapine, and vortioxetine have demonstrated larger effects in studies, though the research supporting them remains limited in scope.5

The duration of treatment is typically long-term, as negative symptoms tend to persist throughout the illness. Doctors carefully monitor for side effects that could worsen negative symptoms, including sedation, movement problems, and a condition called akathisia—an inner sense of restlessness that can look like agitation or anxiety. Adjusting medication doses or switching to different antipsychotics may be necessary if side effects are mimicking or worsening negative symptoms.6

Non-medication treatments play an important supporting role. Psychological therapies, particularly cognitive behavioral therapy (CBT), can help patients develop strategies to cope with negative symptoms and improve motivation. Social skills training helps people rebuild their ability to interact with others, while occupational therapy focuses on practical skills for daily living and employment. These approaches work best when combined with medication rather than used alone.3

Innovative Treatments in Clinical Trials

Researchers are actively investigating new approaches to treating negative symptoms, with several promising candidates currently being tested in clinical trials. These studies aim to address the significant unmet need for more effective treatments beyond currently available options.

One area of investigation involves medications that affect different brain chemical systems than traditional antipsychotics. Several augmentation strategies—adding a second medication to an existing antipsychotic—have shown promise in controlled trials. Simvastatin, a cholesterol-lowering medication, has demonstrated modest benefits for negative symptoms in clinical studies, with an effect size around 0.2 to 0.3. The mechanism may involve reducing inflammation in the brain, which some researchers believe contributes to negative symptoms.5

Minocycline, an antibiotic with anti-inflammatory properties, is being studied as an add-on treatment. Early-phase trials suggest it may help reduce negative symptoms beyond what antipsychotics achieve alone, possibly by protecting brain cells and reducing neuroinflammation. However, larger Phase III trials are needed to confirm these preliminary findings.5

Medications called 5-HT3 receptor antagonists—including ondansetron, granisetron, and tropisetron—are under investigation. These drugs, typically used to prevent nausea, may affect negative symptoms by modulating serotonin pathways in the brain that influence motivation and emotional expression. Small controlled trials have shown positive results, though the benefits remain modest.5

Mood stabilizers including lamotrigine and topiramate have been tested as augmentation treatments in Phase II and Phase III trials. These medications, commonly used for epilepsy and bipolar disorder, may help negative symptoms through effects on glutamate, a major chemical messenger in the brain. Studies have shown effect sizes in the 0.2 to 0.3 range—indicating small but potentially meaningful benefits for some patients.5

Pimavanserin, a novel antipsychotic approved in the United States for hallucinations and delusions in Parkinson's disease, is being investigated as an augmentation treatment for negative symptoms in schizophrenia. This medication works selectively on serotonin receptors without directly blocking dopamine, which may offer advantages for treating negative symptoms without worsening movement problems. Clinical trials are ongoing to determine its effectiveness specifically for negative symptoms.5

Non-pharmacological approaches are also being explored in clinical trials. Transcranial magnetic stimulation (TMS) is a brain stimulation technique that uses magnetic fields to activate specific brain regions. Early studies suggest that TMS targeting areas of the brain involved in motivation and emotional processing may help reduce negative symptoms. This approach is non-invasive and generally well-tolerated, making it an attractive option for patients who don't respond adequately to medications.6

Digital phenotyping—using smartphones and wearable devices to track behavior patterns, activity levels, and social interactions—is being studied as both an assessment tool and potential intervention for negative symptoms. This technology might help identify worsening symptoms earlier and provide personalized feedback to encourage activity and social engagement.6

Some research groups are investigating psychedelic substances, though this remains highly experimental and controversial. The theory is that psychedelics might help "reset" brain networks involved in motivation and emotional processing. However, significant concerns exist about safety in people with schizophrenia, as psychedelics can trigger psychosis. These studies are in very early phases and require extensive safety monitoring.6

The trial phases for these treatments follow a standard progression. Phase I trials test safety and dosing in small groups of healthy volunteers or patients. Phase II trials examine whether the treatment shows effectiveness and continues to be safe in larger groups of patients—typically 100 to 300 people. Phase III trials compare the new treatment to standard care in even larger populations, often involving multiple research centers across different countries. Some studies are being conducted in the United States, Europe (including countries like Poland, Germany, and the United Kingdom), and other regions worldwide.6

Patient eligibility for clinical trials typically requires a confirmed diagnosis of schizophrenia with persistent negative symptoms despite adequate treatment with antipsychotic medication. Trials often exclude patients with active substance abuse, significant medical conditions, or those who are actively psychotic, as these factors can interfere with measuring the specific effects on negative symptoms.

Most common treatment methods

• Second-generation antipsychotics
  • Cariprazine has shown superior effectiveness for negative symptoms compared to some other antipsychotics in controlled trials
  • Amisulpride demonstrates favorable results in large European studies specifically targeting negative symptoms
  • Clozapine shows the largest effect size for reducing negative symptoms and improving functional recovery
  • Olanzapine, asenapine, and other atypical antipsychotics show modest benefits, particularly during active psychosis
• Antidepressant augmentation
  • SSRIs (selective serotonin reuptake inhibitors) added to antipsychotics show generally positive but small effects
  • Duloxetine, mirtazapine, and vortioxetine demonstrate larger effect sizes in limited studies
  • May particularly help when depression coexists with negative symptoms
• Novel medication augmentation strategies
  • Simvastatin (cholesterol medication) shows modest benefits, possibly through anti-inflammatory effects
  • Minocycline (antibiotic) being studied for neuroprotective and anti-inflammatory properties
  • 5-HT3 antagonists (ondansetron, granisetron, tropisetron) under investigation for effects on serotonin pathways
  • Lamotrigine and topiramate (mood stabilizers) tested in Phase II/III trials with small positive effects
  • Pimavanserin investigated as augmentation therapy due to unique mechanism targeting serotonin without blocking dopamine
• Psychological and behavioral therapies
  • Cognitive behavioral therapy (CBT) helps develop coping strategies and improve motivation
  • Social skills training assists in rebuilding interpersonal abilities
  • Occupational therapy focuses on practical daily living and employment skills
  • Most effective when combined with medication rather than used alone
• Brain stimulation techniques
  • Transcranial magnetic stimulation (TMS) targets brain regions involved in motivation and emotional processing
  • Non-invasive approach showing promise in early clinical trials
  • Generally well-tolerated with few side effects
• Lifestyle and self-management approaches
  • Regular physical exercise provides psychological benefits and helps manage medication side effects
  • Healthy diet, particularly Mediterranean-style eating, supports overall health and symptom management
  • Stress management through relaxation techniques, mindfulness, and meditation
  • Structured daily routines help maintain activity and social engagement